ABVC BIOPHARMA, INC. (ABVC): Nasdaq/NYSE listing notice — ABVC BioPharma regains Nasdaq compliance after equity-boosting transactions totaling ~$10.65M

ABVC BIOPHARMA, INC.

Company completed four transactions increasing stockholders' equity by ~$10.65M to meet Nasdaq listing requirement.
Issued 300K shares and 200K pre-funded warrants on July 31, raising $1.75M in equity.
Note conversion of $500K on Aug 1 added $0.5M; $308K note repayment via 176,678 shares added $1M more.
Agreed to acquire 20% of property from Zhonghui for 370K shares, expected to add $7.4M (closing pending).
Nasdaq will continue to monitor compliance; delisting risk remains if not maintained at next periodic report.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.82

ABVC BIOPHARMA, INC. received a nasdaq compliance regained notice regarding stockholders equity.

Exchange: nasdaq
Notice: compliance regained
Deficiency: stockholders equity

Exact text from the filing

July 31, 2023, the Company issued 300,000 shares of its common stock, par value $0.001 per share (“Common Stock”) and 200,000 pre-funded warrants, at an exercise price of $0.01 per share, in a registered direct offering. Pursuant to this transaction, the stockholders’ equity was increased by $1.75M. We also previously disclosed that on August 1, 2023, the holder of $500,000 of Notes (as hereinafter defined) converted such notes at $3.50 per share and received 142,857 shares of Common Stock. As a result of this conversion, the stockholders’ equity was increased by $0.5M. Additionally, as previ

View on SEC.gov

Browse all listing & compliance notices →

ABVC BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-072608

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.